vs

Side-by-side financial comparison of ASHFORD HOSPITALITY TRUST INC (AHT) and TransMedics Group, Inc. (TMDX). Click either name above to swap in a different company.

ASHFORD HOSPITALITY TRUST INC is the larger business by last-quarter revenue ($259.0M vs $160.8M, roughly 1.6× TransMedics Group, Inc.). TransMedics Group, Inc. runs the higher net margin — 65.6% vs -26.8%, a 92.3% gap on every dollar of revenue. On growth, TransMedics Group, Inc. posted the faster year-over-year revenue change (32.2% vs -6.0%). TransMedics Group, Inc. produced more free cash flow last quarter ($19.0M vs $-86.8M). Over the past eight quarters, TransMedics Group, Inc.'s revenue compounded faster (28.8% CAGR vs -7.7%).

Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.

TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.

AHT vs TMDX — Head-to-Head

Bigger by revenue
AHT
AHT
1.6× larger
AHT
$259.0M
$160.8M
TMDX
Growing faster (revenue YoY)
TMDX
TMDX
+38.2% gap
TMDX
32.2%
-6.0%
AHT
Higher net margin
TMDX
TMDX
92.3% more per $
TMDX
65.6%
-26.8%
AHT
More free cash flow
TMDX
TMDX
$105.8M more FCF
TMDX
$19.0M
$-86.8M
AHT
Faster 2-yr revenue CAGR
TMDX
TMDX
Annualised
TMDX
28.8%
-7.7%
AHT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AHT
AHT
TMDX
TMDX
Revenue
$259.0M
$160.8M
Net Profit
$-69.3M
$105.4M
Gross Margin
58.1%
Operating Margin
-2.6%
13.2%
Net Margin
-26.8%
65.6%
Revenue YoY
-6.0%
32.2%
Net Profit YoY
44.2%
1436.9%
EPS (diluted)
$-12.85
$2.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AHT
AHT
TMDX
TMDX
Q4 25
$259.0M
$160.8M
Q3 25
$266.1M
$143.8M
Q2 25
$302.0M
$157.4M
Q1 25
$277.4M
$143.5M
Q4 24
$275.5M
$121.6M
Q3 24
$276.6M
$108.8M
Q2 24
$316.5M
$114.3M
Q1 24
$303.9M
$96.8M
Net Profit
AHT
AHT
TMDX
TMDX
Q4 25
$-69.3M
$105.4M
Q3 25
$-60.1M
$24.3M
Q2 25
$-30.4M
$34.9M
Q1 25
$-20.0M
$25.7M
Q4 24
$-124.2M
$6.9M
Q3 24
$-57.9M
$4.2M
Q2 24
$50.3M
$12.2M
Q1 24
$71.6M
$12.2M
Gross Margin
AHT
AHT
TMDX
TMDX
Q4 25
58.1%
Q3 25
58.8%
Q2 25
61.4%
Q1 25
61.5%
Q4 24
59.2%
Q3 24
55.9%
Q2 24
60.6%
Q1 24
61.9%
Operating Margin
AHT
AHT
TMDX
TMDX
Q4 25
-2.6%
13.2%
Q3 25
4.6%
16.2%
Q2 25
16.3%
23.2%
Q1 25
22.2%
19.1%
Q4 24
-17.8%
7.1%
Q3 24
7.3%
3.6%
Q2 24
42.8%
10.9%
Q1 24
50.2%
12.8%
Net Margin
AHT
AHT
TMDX
TMDX
Q4 25
-26.8%
65.6%
Q3 25
-22.6%
16.9%
Q2 25
-10.1%
22.2%
Q1 25
-7.2%
17.9%
Q4 24
-45.1%
5.6%
Q3 24
-20.9%
3.9%
Q2 24
15.9%
10.7%
Q1 24
23.5%
12.6%
EPS (diluted)
AHT
AHT
TMDX
TMDX
Q4 25
$-12.85
$2.59
Q3 25
$-11.35
$0.66
Q2 25
$-6.88
$0.92
Q1 25
$-4.91
$0.70
Q4 24
$-13.64
$0.19
Q3 24
$-12.39
$0.12
Q2 24
$2.50
$0.35
Q1 24
$5.99
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AHT
AHT
TMDX
TMDX
Cash + ST InvestmentsLiquidity on hand
$66.1M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$-626.4M
$473.1M
Total Assets
$2.8B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AHT
AHT
TMDX
TMDX
Q4 25
$66.1M
Q3 25
$81.9M
Q2 25
$100.0M
Q1 25
$85.8M
Q4 24
$112.9M
Q3 24
$119.7M
$330.1M
Q2 24
$121.8M
$362.8M
Q1 24
$111.1M
$350.2M
Total Debt
AHT
AHT
TMDX
TMDX
Q4 25
$2.5B
Q3 25
$2.6B
Q2 25
$2.6B
Q1 25
$2.7B
Q4 24
$2.6B
Q3 24
$2.7B
Q2 24
$2.8B
Q1 24
$2.9B
Stockholders' Equity
AHT
AHT
TMDX
TMDX
Q4 25
$-626.4M
$473.1M
Q3 25
$-548.7M
$355.2M
Q2 25
$-485.5M
$318.1M
Q1 25
$-446.1M
$266.3M
Q4 24
$-419.2M
$228.6M
Q3 24
$-288.4M
$209.9M
Q2 24
$-225.9M
$189.9M
Q1 24
$-276.8M
$159.5M
Total Assets
AHT
AHT
TMDX
TMDX
Q4 25
$2.8B
$1.1B
Q3 25
$3.0B
$946.0M
Q2 25
$3.1B
$890.5M
Q1 25
$3.1B
$837.5M
Q4 24
$3.2B
$804.1M
Q3 24
$3.3B
$785.6M
Q2 24
$3.3B
$758.6M
Q1 24
$3.5B
$723.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AHT
AHT
TMDX
TMDX
Operating Cash FlowLast quarter
$-15.7M
$34.5M
Free Cash FlowOCF − Capex
$-86.8M
$19.0M
FCF MarginFCF / Revenue
-33.5%
11.8%
Capex IntensityCapex / Revenue
27.5%
9.7%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-135.5M
$133.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AHT
AHT
TMDX
TMDX
Q4 25
$-15.7M
$34.5M
Q3 25
$5.5M
$69.6M
Q2 25
$16.3M
$91.6M
Q1 25
$-25.0M
$-2.9M
Q4 24
$-23.6M
$19.7M
Q3 24
$795.0K
$6.9M
Q2 24
$8.0M
$25.7M
Q1 24
$-46.5M
$-3.4M
Free Cash Flow
AHT
AHT
TMDX
TMDX
Q4 25
$-86.8M
$19.0M
Q3 25
$-226.0K
$61.9M
Q2 25
$-3.6M
$82.5M
Q1 25
$-44.8M
$-29.9M
Q4 24
$-131.6M
$6.1M
Q3 24
$-21.8M
$-41.3M
Q2 24
$-22.9M
$2.0M
Q1 24
$-80.4M
$-47.6M
FCF Margin
AHT
AHT
TMDX
TMDX
Q4 25
-33.5%
11.8%
Q3 25
-0.1%
43.1%
Q2 25
-1.2%
52.4%
Q1 25
-16.2%
-20.8%
Q4 24
-47.8%
5.0%
Q3 24
-7.9%
-38.0%
Q2 24
-7.2%
1.7%
Q1 24
-26.5%
-49.2%
Capex Intensity
AHT
AHT
TMDX
TMDX
Q4 25
27.5%
9.7%
Q3 25
2.1%
5.3%
Q2 25
6.6%
5.8%
Q1 25
7.2%
18.8%
Q4 24
39.2%
11.2%
Q3 24
8.2%
44.3%
Q2 24
9.8%
20.8%
Q1 24
11.2%
45.6%
Cash Conversion
AHT
AHT
TMDX
TMDX
Q4 25
0.33×
Q3 25
2.86×
Q2 25
2.62×
Q1 25
-0.11×
Q4 24
2.87×
Q3 24
1.63×
Q2 24
0.16×
2.11×
Q1 24
-0.65×
-0.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AHT
AHT

Occupancy$190.2M73%
Food And Beverage$51.8M20%
Hotel Other$16.6M6%

TMDX
TMDX

Liver Product$127.0M79%
Heart Product$26.0M16%
Other$5.9M4%
Lung Product$1.9M1%

Related Comparisons